Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI318 plus Paclitaxel in Relapsed Small Cell Lung Cancer
NCT04672928Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Dec 2020
- Primary completion
- Jan 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Small Cell Lung Cancer (SCLC) comparing IBI318 + Paclitaxel with Placebo + Paclitaxel (2 arms). Primary endpoints: Adverse events at 3 months and Objective Remission Rate at 12 months. Started Dec 2020; status: completed.
02
Drugs
reozalimab
03
Conditions
Small Cell Lung Cancer (SCLC)
Beyond the preview
Go deeper on NCT04672928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672928.